Results released
Open the filing on sec.gov
Niagen Bioscience, Inc. (NAGE)
Nasdaq: NAGE · Medicinal Chemicals & Botanical Products · Los Angeles, CA · filing with the SEC since 2007
Grade6.8
◀ Past 5.8● Present 7.0▶ Future 7.7
The companyfiscal 2025, as filed
Revenue$129M+29.9%
Net income$17.4M+103.3%
Earnings per share$0.20+81.8%
Operating cash flow$13.5M+11.5%
Cash$64.8M+45.1%
Debtn/a
Shareholders’ equity$76.5M+66.0%
Shares, diluted79.2M+4.3%
Return on equity22.7%
The recordfrom its filings
Filings in 202633
Newest filingNov 4 · 8-K
Annual reportMar 4, 2026
Quarterly reportNov 4, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted21
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $122MNet income $10.2MCash from operations $4.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Quarterly report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.